OTCMKTS:PHMMF Pharma Mar (PHMMF) Stock Price, News & Analysis $96.20 +15.29 (+18.90%) As of 10:21 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartHeadlinesShort InterestBuy This Stock About Pharma Mar Stock (OTCMKTS:PHMMF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Pharma Mar alerts:Sign Up Key Stats Today's Range$96.20▼$96.2050-Day Range$80.91▼$102.0852-Week Range$34.26▼$105.60Volume100 shsAverage Volume943 shsMarket Capitalization$1.73 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingStrong Buy Company OverviewPharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.Read More… Pharma Mar Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks1st Percentile Overall ScorePHMMF MarketRank™: Pharma Mar scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Pharma Mar.Read more about Pharma Mar's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioPharma Mar has a P/B Ratio of 8.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Pharma Mar's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted0.22% of the outstanding shares of Pharma Mar have been sold short.Short Interest Ratio / Days to CoverPharma Mar has a short interest ratio ("days to cover") of 198, which indicates bearish sentiment.Change versus previous month Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPharma Mar does not currently pay a dividend.Dividend GrowthPharma Mar does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.22% of the outstanding shares of Pharma Mar have been sold short.Short Interest Ratio / Days to CoverPharma Mar has a short interest ratio ("days to cover") of 198, which indicates bearish sentiment.Change versus previous month News and Social Media1.5 / 5News SentimentN/A News SentimentPharma Mar has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Pharma Mar insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.88% of the stock of Pharma Mar is held by insiders.Read more about Pharma Mar's insider trading history. Receive PHMMF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharma Mar and its competitors with MarketBeat's FREE daily newsletter. Email Address PHMMF Stock News HeadlinesExploring High Growth Tech Stocks In Europe May 2025May 16, 2025 | finance.yahoo.comExploring High Growth Tech Stocks in Europe April 2025April 14, 2025 | finance.yahoo.comTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.May 23, 2025 | Porter & Company (Ad)Pharma Mar’s Credit Rating Maintained at ‘BB+’April 4, 2025 | tipranks.comPharma Mar Implements Share Delivery Plan to Boost Employee EngagementApril 2, 2025 | tipranks.com3 European Growth Stocks With Insider Ownership Seeing Up To 52% Earnings GrowthMarch 27, 2025 | finance.yahoo.comPharma Mar Releases 2024 Director Remuneration ReportFebruary 28, 2025 | tipranks.comHigh Insider Ownership Growth Companies To Watch In February 2025February 21, 2025 | finance.yahoo.comSee More Headlines PHMMF Stock Analysis - Frequently Asked Questions How have PHMMF shares performed this year? Pharma Mar's stock was trading at $81.07 at the beginning of 2025. Since then, PHMMF shares have increased by 18.7% and is now trading at $96.20. View the best growth stocks for 2025 here. How do I buy shares of Pharma Mar? Shares of PHMMF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today5/23/2025Next Earnings (Estimated)7/28/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Private households Sub-IndustryN/A Current SymbolOTCMKTS:PHMMF Previous SymbolNASDAQ:PHMMF CIKN/A Webwww.pharmamar.com Phone(491) 846-6000Fax34-91-846-6001Employees509Year Founded1986Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.14 Current Ratio2.55 Quick Ratio2.01 Sales & Book Value Annual Sales$171.15 million Price / Sales8.51 Cash Flow$0.35 per share Price / Cash Flow231.27 Book Value$11.62 per share Price / Book6.96Miscellaneous Outstanding Shares18,010,000Free FloatN/AMarket Cap$1.46 billion OptionableNot Optionable Beta0.25 Social Links 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (OTCMKTS:PHMMF) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharma Mar, S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharma Mar With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.